Brainomix joins forces with Boehringer Ingelheim to help save stroke victims
Oxford – An ambitious collaboration between Brainomix, an emerging British business, and Boehringer Ingelheim, one of the world’s largest drug companies, is poised to expedite and improve treatment of stroke, the second biggest killer disease in Europe.
Congenica – Parkwalk closes investment
We are delighted to announce that the Parkwalk Opportunities Fund and the Parkwalk Technology Fund VII have invested in a $10m Series ‘B’ financing round for Congenica Limited, which spun out of the Wellcome Trust Sanger Institute and Department… Read More
Brainomix – International Journal of Stroke Publication
Oxford – A new clinical study was conducted by Anglia Ruskin Clinical Trials Unit reporting the performance of e-ASPECTS. In this multi-centre study, non-contrast enhanced computed tomography (NCCT) images from ischemic stroke patients were evaluated by e-ASPECTS and… Read More
Brainomix – Parkwalk closes follow-on investment
We have recently closed an investment in Brainomix for the Parkwalk UK Tech Fund VII and the Opportunities Fund. Brainomix is aiming to improve stroke treatment dramatically by developing software that gives all hospitals and clinics access to reliable diagnoses… Read More
